Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 21, Issue 3, 2001, Pages 365-371

  Collins, Alan R ^a   Meehan, Woerner P ^a   Kintscher, Ulrich ^a,c,d   Jackson, Simon ^a   Wakino, Shu ^a   Noh, Grace ^a   Palinski, Wulf ^e   Hsueh, Willa A ^a,b   Law, Ronald E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HUMBOLDT UNIVERSITY   (Germany)

^d DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Diabetes mellitus; Pharmacology

Indexed keywords

GLUCOSE; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TROGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CARBOHYDRATE DIET; CARDIOVASCULAR RISK; CELL MIGRATION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPID DIET; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; TREATMENT OUTCOME; XANTHOMA;

EID: 0035093258     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.21.3.365     Document Type: Article

References (40)

1. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein
2. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
3. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo
4. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction
5. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells
6. Expression and function of PPARgamma in rat and human vascular smooth muscle cells
7. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance: Effects of troglitazone
8. Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus
9. Activation of PPARgamma inhibits macrophage proliferation and migration: Possible therapeutic effectiveness of thiazolidinediones on diabetic vascular complications
10. PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells
11. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
12. Pioglitazone reduces smooth muscle cell density of rat carotid arterial intima induced by balloon catheterization
13. Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy
14. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: A serial intravascular ultrasound study
15. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators
16. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL
17. Thiazolidinediones in the treatment of insulin resistance and type II diabetes
18. Cardiovascular complications of diabetes mellitus: What we know and what we need to know about their prevention
19. Lessons from sudden coronary death: A comprehensive morphological classification scheme for atherosclerotic lesions
20. Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice
21. Western-type diets induce insulin resistance and hyperinsulinemia in LDL receptor-deficient mice but do not increase aortic atherosclerosis compared with normoinsulinemic mice in which similar plasma cholesterol levels are achieved by a fructose-rich diet
22. Hypercholesterolemia exacerbates transplant arteriosclerosis via increased neointimal smooth muscle cell accumulation: Studies in apolipoprotein E knockout mice
23. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree
24. Quantitation of atherosclerosis in murine models: Correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice
25. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss
26. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects
27. Altered pressure-natriuresis in obese Zucker rats
28. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus
29. Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes
30. A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone
31. Atherosclerosis is an inflammatory disease
32. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice
33. Troglitazone inhibits angiotensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells
34. Troglitazone has a scavenging effect on reactive oxygen species
35. Dietary beta-carotene and alpha-tocopherol combination does not inhibit atherogenesis in an apoE-deficient mouse model
36. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in apoE-deficient mice
37. Dietary antioxidants inhibit development of fatty streak lesions in the LDL receptor-deficient mouse
38. Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice
39. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
40. Vitamin E supplementation and cardiovascular events in high-risk patients: The heart outcomes prevention evaluation study investigators